GLP-1 ব্যাখ্যা: ভাৰতীয় ৰোগীসকলৰ সম্পূর্ণ গাইড
Semaglutide বা tirzepatide শুনে right for you কি না ভেবাছন—আপুনি একা নন। GLP-1 RA worldwide type 2 diabetes আৰু obesity approach বদলেছে—India exception নহয়। guide GLP-1 কী, body-তে কেনেকৈ কাজ, Indian patient RSSDI, ICMR, CDSCO framework-এ access, cost, safety navigate-এ কি matter। newly diagnosed type 2, normal-range BMI central obesity, family member option explore—drug class literacy brand marketing নহয় productive medical conversation foundation। South Asian unique metabolic pattern, lower insurance coverage, 2026 growing generic access drug-class literacy valuable।
Short answer
GLP-1 ৰিসেপ্টৰ এগোনিষ্ট (GLP-1 RA) injectable আৰু oral ঔষধ শ্ৰেণী যা gut hormone mimic কৰে appetite কমায়, পেট খালী ধীৰ কৰে, blood sugar control উন্নত কৰে। ভাৰতত টাইপ ২ ডায়েবিটিছ আৰু নির্বাচিত স্থূলতায় BMI ≥27.5 kg/m² বা comorbidity-সহ ≥25-এ prescribe। doctor prescription, CDSCO-approved sourcing, gradual dose titration দৰকাৰ। RSSDI আৰু ICMR guideline Indian clinician use shape। Kesho শুধু education—prescribe/sell নহয়। purchase-এর আগে product approval verify।
Key takeaways
- •GLP-1 RA drug class—single product নহয়—natural gut hormone mimic কৰে blood sugar improve আৰু appetite reduce।
- •ভাৰতত RSSDI আৰু ICMR earlier BMI threshold (≥27.5 বা comorbidity-সহ ≥25)—South Asian lower body weight-এ metabolic disease।
- •সকলো GLP-1 RA Schedule H prescription medicine; CDSCO unapproved import আৰু social-media seller-এর বিরুদ্ধে সতৰ্ক।
- •Benefit weeks-এ dose titration-এ build; first month nausea common, ছোট meal আৰু gradual dose increase-এ improve।
- •Medication Indian dietary pattern, physical activity, regular monitoring-এ best—standalone shortcut নহয়।
GLP-1 কি?
GLP-1 (glucagon-like peptide-1) খাওয়ার পর gut release hormone। blood sugar rise-এ pancreas insulin signal, glucagon (blood sugar raise hormone) reduce, brain full signal। GLP-1 RA এই hormone mimic medication। drug class—single brand নহয়—semaglutide, liraglutide, dulaglutide, dual GIP/GLP-1 agent tirzepatide। ভাৰতত Schedule H drug: registered medical practitioner valid prescription ছাড়া dispense নহয়। CDSCO class প্রতিটি product approval, labelling, pharmacovigilance regulate। drug class বোঝা brand marketing trap ছাড়া informed doctor conversation। অনেক patient প্ৰথম GLP-1 RA metformin আৰু lifestyle alone HbA1c control insufficient, বা modest BMI scale-এ excess weight insulin resistance fatty liver drive। RSSDI clinical practice recommendation glycaemic target first-line miss-এ type 2 diabetes pathway-এ GLP-1 RA important option recognise।
- GLP-1 ৰিসেপ্টৰ এগোনিষ্ট
- Pancreas, brain, gut-এ GLP-1 receptor activate কৰে blood sugar control improve আৰু appetite reduce medication।
GLP-1 ৰিসেপ্টৰ এগোনিষ্ট body-তে কেনেকৈ কাম কৰে?
GLP-1 RA নিলে sequence-এ কয়েকটি ঘটে। প্ৰথম pancreas insulin release stimulate—blood glucose elevated হ'লে only, sulfonylurea-এর মতো older diabetes drug-এর চেয়ে low blood sugar risk কম। দ্বিতীয় gastric emptying slow—food stomach-এ longer, smaller portion satisfied। তৃতীয় brain appetite centre-এ act, craving emotional eating trigger reduce। STEP programme semaglutide, SURMOUNT tirzepatide trial lifestyle change-এ meaningful weight loss HbA1c improvement। dose titrate upward weeks-এ gradually build—first two-three months patience। first weeks nausea common, body adapt slow dose increase (dose titration) doctor guide—improve। Indian patient large traditional meal-এ delayed stomach emptying unfamiliar; smaller frequent portion single heavy dinner-এর চেয়ে better।
ভাৰতত GLP-1-এর approved use কি?
ভাৰতত GLP-1 RA primarily adult type 2 diabetes diet, exercise, metformin first-line insufficient। RSSDI class position better glycaemic control, cardiovascular risk, obesity, CKD, other medicine hypoglycaemia concern। obesity management ICMR national guideline RSSDI consensus Western-এর চেয়ে lower BMI threshold—South Asian lower body weight metabolic complication। BMI 27.5 kg/m²+, বা prediabetes, fatty liver, hypertension, dyslipidaemia comorbidity-সহ 25 kg/m²+ appropriate patient pharmacotherapy consider। final eligibility treating physician full medical history, current medicine, investigation review। cardiovascular outcome trial established heart disease high-risk patient glucose beyond benefit। type 1 diabetes indicated নহয়; diabetic ketoacidosis insulin substitute নহয়।
Kesho GLP-1 medication prescribe বা sell কৰে না। article educational। personalised medical advice qualified endocrinologist, internal medicine specialist, cardiologist consult।
Indian BMI threshold Western guideline-এর চেয়ে কেন আলাদা?
Indian South Asian population frequently "thin-fat" phenotype: scale-এ normal/modest BMI, higher visceral (belly) fat, lower muscle mass। insulin resistance, fatty liver, early type 2 diabetes link। BMI 26 Mumbai Europe same BMI-এর চেয়ে metabolic risk বেশi। RSSDI ICMR earlier intervention recommend। conventional chart "normal" weight central obesity, elevated HbA1c, ultrasound fatty liver doctor GLP-1 broader metabolic plan discuss। waist circumference South Asia men often 90 cm+, women 80 cm+ clinician BMI alongside practical measure। body composition scale number alone—Western online calculator Indian patient misleading self-assessment।
ভাৰতত GLP-1 medication legally access কেনেকৈ?
ভাৰতত GLP-1 RA innovator product আৰু increasingly CDSCO-approved generic semaglutide patent development follow। monthly out-of-pocket approximately ₹8,000–₹25,000 molecule, dose, city—most family significant expense। licensed pharmacy valid prescription purchase। CDSCO advisory unapproved import, compounded formulation, social-media steep discount without prescription warn। medication CDSCO approval, proper labelling, batch, expiry verify। cold-chain injectable pen প্ৰথম ব্যৱহাৰের আগে 2°C–8°C refrigeration। first use-এর পর most pen 30°C room temperature several weeks manufacturer CDSCO-approved guideline। metro pharmacist cold-chain familiar; tier-2 tier-3 dispensing counter storage confirm।
GLP-1 RA common diabetes medicine-এর সঙ্গে compare
| Feature | GLP-1 receptor agonists | Metformin | Sulfonylureas |
|---|---|---|---|
| Primary action | Mimics GLP-1 hormone; reduces appetite | Reduces liver glucose output | Stimulates insulin release |
| Weight effect | Usually promotes loss | Neutral or slight loss | Often promotes gain |
| Hypoglycaemia risk alone | Low | Very low | Moderate to high |
| Route in India | Injection (weekly/daily) or oral tablet | Oral tablet | Oral tablet |
| Typical RSSDI position | After metformin if targets unmet | First-line for most T2D | Declining use due to hypoglycaemia/weight |
Medically reviewed
Dr. Ananya Mehta, MD, DM Endocrinology
Consultant Endocrinologist, India
This article has been reviewed by our medical advisory team, including endocrinologists, internal medicine specialists, and cardiologists, and is based on current scientific evidence and Indian clinical guidelines. Last reviewed: June 2026.
Last medically reviewed: Jun 26, 2026